Bone-Tech
It is our mission to develop a portfolio of bone healing therapeutics to improve quality of life for patients
Osteoarthritis: A disease with high unmet medical need
- Knee osteoarthritis (OA) is a leading cause of disability
- There is no disease modifying osteoarthritis drug available
- Osteoarthritis is a disease of the whole joint, including subchondral bone, which is of low quality and unable to support the overlying cartilage appropriately
Bone Marrow Lesions: a promising target for treatment of Osteoarthritis
- One of the primary causes of pain and loss of function in Osteoarthritis are Bone Marrow Lesions (BMLs) in subchondral bone
- BMLs are caused by impaired bone remodeling resulting in low mineralization and microfractures
- BMLs occur in 50-85% of patients, and are:
- Associated with pain
- Prognostic for cartilage loss
- Predictive for knee replacement
BT002: first disease modifying osteoarthritis drug
- Efficacy demonstrated in animal model and bone from human osteoarthritis patients
- Proven mechanism of action in man
- Minimally invasive local delivery with no systemic side effects
- Expansion also into hips, hands, shoulder and lower back pain
Proprietary Microfluidic Emulsification
On a unique small chip with up to 100 identical channels emulsion droplets are continuously produced in a fully controlled, predictable and scalable manner.
BT002: open for partnering
- First disease modifying osteoarthritis drug resulting in pain relief AND potential to delay/eliminate the need for knee replacement
- Preclinical Proof of Principle demonstrated & proven mechanism of action in man
- Stable and scalable technology and process
- 505(b)(2) / Hybrid IND regulatory route; faster, cheaper & lower risk path to market
- Strong IP portfolio covering composition of matter (EU granted) and process patents beyond 2040
- Blockbuster sales potential
- Expansion also into hips, hands, shoulder and lower back pain
Experienced Team
-
Co-CEO Science, Co-founder
Jan Gossen, PhD
18 years pharma experience at Organon/Schering-Plough/MSD, Amgen. Strong background in bone biology and heading projects up to Phase 2 in clinic. Entrepeneur – CEO and founder Osteo-Pharma. Successfully applied for 2M EUR RVO grant.
-
Co-CEO Finance, Co-founder
Rene Hansen
25 yrs pharma and technology industry experience, and has held executive positions in Teva, UCB, Amazon and Philips, both in Europe, USA and Asia. Co-founded 4 different start-ups, lead several scale-ups and funding rounds, created 2 exits. Educational background in IESE Business School & Tech University Delft. Add UCB Amazon.
-
Chief Commercial Officer, Co-founder
Scott Fleming
28 years pharma and drug delivery entrepreneur, consultant and executive. Co-founded 5 start-ups & JVs, led financing rounds, clinical trials, license deals and exits. Including specialty pharma MicroDose Therapeutx, sold to Teva for $165M plus royalties.
-
Chief Operations Officer
Marion Blomenröhr, PhD
Portfolio, program, alliance and people manager with 18 years of experience in R&D of NCEs, NBEs, generics and biosimilars in different therapeutic areas including bone and pain. Delivered clinical candidates, clinical batches, CTA’s and PoC in human, launched generic products, scouted new opportunities and negotiated access & option agreement